BLTE Insider Trading Activity and SEC Form 4 Filings
BLTE insider trading summary
Over the past 12 months, insiders at Belite Bio, Inc (BLTE) reported 104 sales worth $7.9M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $7.9M.
Latest BLTE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $2K (12 @ $168.21) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $20K (120 @ $165.49) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $13K (78 @ $167.59) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $8K (50 @ $166.44) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $2K (14 @ $169.36) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $340 (2 @ $170.02) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $4K (24 @ $164.64) |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sell | $33K (200 @ $163.63) |
| Aug 12, 2026 | Yu-Hsin Lin | Chief Executive Officer | Sell | $26K (142 @ $180.00) |
| Aug 12, 2026 | Hao-Yuan Chuang | Chief Financial Officer | Sell | $40K (223 @ $180.57) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.